Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design

2017 ◽  
Vol 189 ◽  
pp. 120-127 ◽  
Author(s):  
Francesco Violi ◽  
Giovanni Targher ◽  
Annarita Vestri ◽  
Roberto Carnevale ◽  
Maurizio Averna ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Disease ◽  
Randomized Trial ◽  
Disease Progression ◽  
Study Design ◽  
Diabetic Patients ◽  
Renal Disease Progression ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals The Severity of Diabetic Retinopathy Is an Independent Factor for the Progression of Diabetic Nephropathy

2020 ◽  
Vol 10 (1) ◽  
pp. 3
Author(s):  
Shi-Chue Hsing ◽  
Chia-Cheng Lee ◽  
Chin Lin ◽  
Jiann-Torng Chen ◽  
Yi-Hao Chen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Retinopathy ◽  
Kidney Disease ◽  
Renal Disease ◽  
Disease Progression ◽  
Renal Disease Progression ◽  
Hazard Ratios ◽  
Stage Renal Disease ◽  
End Stage

(1) Background: It has rarely been studied whether the severity of diabetic retinopathy (DR) could influence renal disease progression in end-stage renal disease (ESRD) and chronic kidney disease (CKD) in patients with type 2 diabetes. The aim of this study was to evaluate renal disease progression in ESRD and CKD according to DR severity in patients with type 2 diabetes. (2) Methods: We included 1329 patients and divided the cohort into two end-points. The first was to trace the incidence of ESRD in all enrolled participants and the other was to follow their progression to CKD. (3) Results: Significantly higher crude hazard ratios (HRs) of ESRD incidence in all enrolled participants were noted, and this ratio increased in a stepwise fashion. However, after adjustment, DR severity was not associated with ESRD events. Therefore, a subgroup of 841 patients without CKD was enrolled to track their progression to CKD. Compared with no diabetic retinopathy, the progression of CKD increased in a stepwise fashion, from mild nonproliferative diabetic retinopathy (NPDR) to moderate NPDR, to severe NPDR and to proliferative diabetic retinopathy (PDR), both in the crude and adjusted models. (4) Conclusions: The severity of retinopathy appeared to be associated with renal lesions and the development of CKD. Our findings suggest that the severity of DR is a risk factor for progression to CKD. Therefore, diabetic retinopathy is useful for prognosticating the clinical course of diabetic kidney disease.

High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes

Nitric Oxide ◽  
2016 ◽  
Vol 55-56 ◽  
pp. 18-24 ◽  
Author(s):  
Joost C. van den Born ◽  
Anne-Roos S. Frenay ◽  
Stephan J.L. Bakker ◽  
Andreas Pasch ◽  
Jan-Luuk Hillebrands ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Disease ◽  
Disease Progression ◽  
Sulfate Concentration ◽  
Renal Disease Progression ◽  
Reduced Risk

scholarly journals Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes

Diabetes Care ◽  
2012 ◽  
Vol 35 (10) ◽  
pp. 2061-2068 ◽  
Author(s):  
P. Ruggenenti ◽  
E. L. Porrini ◽  
F. Gaspari ◽  
N. Motterlini ◽  
A. Cannata ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Disease ◽  
Disease Progression ◽  
Glomerular Hyperfiltration ◽  
Renal Disease Progression

scholarly journals Lack of association between anemia and renal disease progression in Chinese patients with type 2 diabetes

2015 ◽  
Vol 7 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Liubao Gu ◽  
Qinglin Lou ◽  
Haidi Wu ◽  
Xiaojun Ouyang ◽  
Rongwen Bian
Keyword(s):  
Type 2 Diabetes ◽  
Renal Disease ◽  
Disease Progression ◽  
Chinese Patients ◽  
Renal Disease Progression

Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria – A double-blind, placebo-controlled randomized trial

2006 ◽  
Vol 66 (07) ◽  
pp. 3-10 ◽  
Author(s):  
M. Rodríguez-Morán ◽  
G. González-González ◽  
M.V. Bermúdez-Barba ◽  
C.E. Medina de la Garza ◽  
H.E. Tamez-Pérez ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Urinary Protein Excretion ◽  
Urinary Protein ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Protein Excretion ◽  
Type 2 Diabetic

scholarly journals Evaluation of the Effect of Curcumin and Zinc Co-Supplementation on Glycemic Measurements, Lipid Profiles, Inflammatory and Antioxidant Biomarkers in Overweight or Obese Pre-Diabetic Patients: A study Protocol for a Randomized Double-Blind Placebo-Controlled Phase 2 Clinical Trial

2020 ◽  
Author(s):  
Majid Karandish ◽  
Hassan Mozaffari-khosravi ◽  
Seyed Mohammad Mohammadi ◽  
bahman cheraghian ◽  
Maryam Azhdari
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Profiles ◽  
Trial Registration ◽  
Diabetic Patients ◽  
Double Blind ◽  
Double Blind Placebo

Abstract Background: The prevalence of prediabetes is increasing worldwide. Unfortunately, prediabetes is related to non-communicable diseases. A high risk of developing type 2 diabetes mellitus (T2DM) is reported in people with prediabetes. Curcumin, a polyphenol, might lead to its therapeutic role in obesity and some obesity-related metabolic diseases. Zinc is a trace element that plays a key role in the synthesis and action of insulin, carbohydrate metabolism, and decreasing inflammation. There has been no clinical trial of zinc and curcumin co-supplementation in patients with prediabetes. In previous studies, the single administration of zinc or curcumin hasn’t been conducted on many of the studied markers in pre-diabetic patients. Methods: The propose of this randomized double-blind placebo-controlled clinical trial is to investigate the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, inflammatory and antioxidant biomarkers among 84 pre-diabetic patients with body mass index (BMI) between 25 and 35. Also, liver enzyme, serum zinc, urine zinc, blood pressure, anthropometric parameters, quality of life, adherence to co-supplementation, the side effects of co-supplementation, physical activity, and dietary intake will be assessed. Women or men (18-50 years old, for women: 18 years - before menopause) will be followed for three months (90 days). This study will be conducted at Yazd Diabetes Research Clinic, Shahid Sadoughi University of Medical Sciences. Discussion: A diet rich in antioxidants, polyphenols, and phytochemicals has been shown to have a beneficial role in prediabetes. According to the beneficial properties of curcumin or zinc and inadequate evidence, RCTs are needed to assess the effect of curcumin and zinc co-supplementation in native prediabetes patients. We hope the results of the present trial, negative or positive, fill this gap in the literature and facilitate the approach for a much larger, multi-center clinical trial. In conclusion, a synergic effect of co-supplementation along with a weight-loss diet may delay the progression to type 2 diabetes mellitus.Trial registration: The project is a registered clinical trial (Registration number: IRCT20190902044671N1, Iranian Registry of Clinical Trials (IRCT), registered October 11, 2019.

Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy

2006 ◽  
Vol 290 (1) ◽  
pp. E54-E59 ◽  
Author(s):  
Lucilla D. Monti ◽  
Emanuela Setola ◽  
Gabriele Fragasso ◽  
Riccardo P. Camisasca ◽  
Pietro Lucotti ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Lipid Oxidation ◽  
Ischemic Cardiomyopathy ◽  
Glucose Oxidation ◽  
Diabetic Patients ◽  
Vascular Effects ◽  
Type 2 Diabetic Patients ◽  
Double Blind ◽  
Endothelin 1

The aim of the present study was to evaluate the effect of prolonged inhibition of β-oxidation on glucose and lipid muscle forearm metabolism and cGMP and endothelin-1 forearm release in patients with type 2 diabetes mellitus and ischemic cardiomyopathy. Fifteen patients were randomly allocated in a double-blind cross-over parallel study with trimetazidine (20 mg tid) or placebo lasting 15 days. At the end of each period, all patients underwent euglycemic hyperinsulinemic clamps with forearm indirect calorimetry and endothelial balance of vasodilator and vasoconstricor factors. Compared with placebo, trimetazidine induced 1) an increase in insulin-induced forearm glucose uptake and glucose oxidation accompained by a reduction in forearm lipid oxidation and citrate release and 2) a decrease of endothelin-1 release paralleled by a significant increase in forearm cGMP release. Forearm glucose oxidation significantly correlated with cGMP release ( r = 0.37, P < 0.04), whereas forearm lipid oxidation positively correlated with endothelin-1 release ( r = 0.40, P < 0.03). In conclusion, for the first time, we demonstrated that insulin-induced forearm glucose oxidation and forearm cGMP release were increased whereas forearm endothelin-1 release was decreased during trimetazidine treatment. Muscle's metabolic and vascular effects of trimetazidine add new interest in the use of trimetazidine in type 2 diabetic patients with cardiovascular disease.

Sign in / Sign up

Export Citation Format

Share Document